secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-150883
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis CEO Anthony Sun resigns; Kimberly Blackwell appointed as CEO effective May 16
--------------------------------------------------------------------------------

- Anthony Y. Sun resigned as President, CEO and Chairman effective May 10; Kevin Bunker appointed interim PEO.
- Kimberly Blackwell appointed President and CEO effective ~May 16; David Johnson named Chairman.
- Blackwell receives $680k base salary, 60% target bonus, $250k sign-on bonus (pro-rated clawback within 1 year).
- Equity grants: option for 3.0% of outstanding shares (4-yr vest) and 0.75% (vests on FDA approval of a product or change in control).
- Sun receives severance: 18 months base salary plus prorated 2022 target bonus, continued vesting of equity up to Feb 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000119312522150883/0001193125-22-150883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000119312522150883/d361453d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer